<p>The previously used term cardiorenal disease (CRD) captures the complexity of the numerous interactions between cardiac and renal insufficiency much better than the later used definition of cardiorenal or cardiorenal metabolic syndrome, even if it insufficiently reflects the complexity of CRD. Heart failure and chronic kidney disease and the associated comorbidities are closely interlinked pathophysiologically, prognostically and now also therapeutically. The importance of heart failure with preserved ejection fraction (HFpEF) is also increasingly coming to the forefront not only in the pathophysiology but also the treatment. Previous concepts, such as sequential nephron blockade are being replaced by newer interlocking and prognosis-improving concepts such as panrenal diuretic treatment. In addition, new comprehensive and system-modulating innovative treatment options are leading to a&#xa0;paradigm shift from organ-centered treatment, symptom control and relief to real improvement of the prognosis. With these new cardiorenal prognosis-improving drugs (CAREPID), comprehensive multiorgan and prognosis-improving treatment options are now available for CRD.</p>